296 related articles for article (PubMed ID: 17548453)
1. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
[TBL] [Abstract][Full Text] [Related]
2. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
[TBL] [Abstract][Full Text] [Related]
3. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
4. Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.
Strueby L; Nair B; Kirk A; Taylor-Gjevre RM
Scand J Rheumatol; 2005; 34(6):485-8. PubMed ID: 16393774
[TBL] [Abstract][Full Text] [Related]
5. [Profile of efficacy and safety in the treatment of remittent-recurrent multiple sclerosis with interferon beta-1b].
Río J; Marzo ME; Tintoré M; Borrás C; Montalbán X
Neurologia; 1998 Nov; 13(9):422-6. PubMed ID: 9883016
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
Feinstein A; O'Connor P; Feinstein K
J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
[TBL] [Abstract][Full Text] [Related]
7. [Evolution and adverse effects in patients with remittent-recurrent multiple sclerosis treated with interferon beta 1b. The influence of patient's weight and height].
García-Moreno JM; Navarro G; Duque P; Gamero MA; Gata JM; Gálvez JL; Izquierdo G
Neurologia; 1999 Apr; 14(4):154-8. PubMed ID: 10363489
[TBL] [Abstract][Full Text] [Related]
8. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
[TBL] [Abstract][Full Text] [Related]
9. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
10. The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients.
Varoglu AO; Varoglu E; Bayraktar R; Aygul R; Ulvi H; Yildirim K
J Back Musculoskelet Rehabil; 2010; 23(1):25-9. PubMed ID: 20231786
[TBL] [Abstract][Full Text] [Related]
11. Cotton wool spots associated with interferon beta-1 alpha therapy.
Longmuir R; Lee AG; Rouleau J
Semin Ophthalmol; 2007; 22(1):49-53. PubMed ID: 17366120
[TBL] [Abstract][Full Text] [Related]
12. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
13. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
Warabi Y; Matsumoto Y; Hayashi H
J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L; Neves M; Cardoso E; Melo A
J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.
Duchini A
Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585
[No Abstract] [Full Text] [Related]
17. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
[TBL] [Abstract][Full Text] [Related]
18. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
19. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
Tamura S; Warabi Y; Matsubara S
J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
[TBL] [Abstract][Full Text] [Related]
20. Fixed drug eruption with interferon-beta-1b.
Tai YJ; Tam M
Australas J Dermatol; 2005 Aug; 46(3):154-7. PubMed ID: 16008645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
